Raymond James downgraded Editas Medicine (EDIT, Financials) from outperform to market perform, citing extended development timelines and uncertainties surrounding its in vivo gene-editing program.
With the next program update planned in the first quarter of 2025, the investment company highlighted Editas has now turned its attention to in vivo editing for treating sickle cell illness and beta thalassemia. Although this technique might provide a safety benefit by maybe removing the requirement for myeloablative conditioning, Raymond James voiced doubts regarding its effectiveness relative to the approved ex vivo technique.
The company also underlined that Editas is trying to out-license its reni-cel treatment, a procedure it described as difficult given the low commercialization of rival treatments. Particularly, Vertex Pharmaceuticals (VRTX, Financials) and CRISpen Therapeutics (CRSP, Financials) have created a competing treatment called Casgevy with revised sales projections shortly.
New results from a Phase 1/2/3 study of reni-cel is slated to be presented at the American Society of Hematology meeting from December 7 to 10, Raymond James also said.
As Editas negotiates strategy changes and competitive pressures in the biotechnology industry, this downgrading reflects more general questions over the feasibility and market readiness of the company's gene-editing technologies.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。